The federal Substance Abuse and Mental Health Services Administration (SAMHSA) released a proposed rule that would permanently allow providers to prescribe buprenorphine using telehealth for opioid use disorder treatment without requiring an in-person physical evaluation. With comments due on or before Feb. 14, 2023, the proposed rule also includes a change to the consent process required for telehealth visits, among other proposed changes.
